Trials / Withdrawn
WithdrawnNCT02433236
Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
A Phase 2, Multi-Centre, Open Label Extension Study of Fostamatinib in the Treatment of IgA Nephropathy for Patients Who Participated in Study C-935788-050
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Rigel Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 72 Years
- Healthy volunteers
- Not accepted
Summary
Phase 2, multi-center, open label extension study to evaluate 2 dose regimens of fostamatinib in approximately 25 subjects. The study will consist of 11 visits over 15 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fostamatinib Disodium tablet 100 mg | |
| DRUG | Fostamatinib Disodium tablet 150 mg |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2015-09-01
- First posted
- 2015-05-04
- Last updated
- 2015-10-23
Source: ClinicalTrials.gov record NCT02433236. Inclusion in this directory is not an endorsement.